An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
India Globalization Capital Appoints Claudia Grimaldi to its Board of Directors
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
India Globalization Capital has appointed Claudia Grimaldi as a non-independent Director effective March 23, 2022. With nearly 12 years at IGC, she brings extensive experience in SEC and NYSE compliance and is currently the Vice President and Chief Compliance Officer. Ms. Grimaldi aims to offer diverse perspectives and advance the company’s commitment to achieving ESG goals, particularly for the IGC-AD1 project targeting Alzheimer’s disease. IGC continues to focus on cannabinoid-based therapies and has recently completed a Phase 1 clinical trial.
Positive
Claudia Grimaldi's appointment as a director may bring fresh perspectives and leadership experience.
Ms. Grimaldi's long tenure with IGC indicates deep knowledge of the company's operations and goals.
The recent completion of the Phase 1 clinical trial for IGC-AD1 demonstrates progress in the company's therapeutic developments.
Negative
Ms. Grimaldi's non-independent status could raise concerns about governance and oversight.
POTOMAC, Md.--(BUSINESS WIRE)--
India Globalization Capital, Inc. (NYSE American: IGC) announces that the Board has appointed Ms. Claudia Grimaldi as a non-independent Director, effective March 23, 2022. IGC now has 5 directors including a majority who are independent.
Ms. Grimaldi has been with IGC for almost 12 years with increasing responsibilities including managing SEC and NYSE filings, regulatory compliance, and disclosures. She is currently Vice President, Principal Finance Officer, and Chief Compliance Officer. She is also the Managing Director of Hamsa Biochem SAS, our subsidiary in Colombia, as well as a director of our subsidiary in India.
Ms. Grimaldi stated: “I hope to bring diversity of thought and perspective to the IGC Board. I have seen IGC overcame many obstacles and grow over the last 12 years. I feel that we are in a great place with IGC-AD1 and its potential to alleviate neuropsychiatric symptoms like agitation, anxiety, and depression in patients with Alzheimer’s disease. Working towards this possibility is a huge motivator for me and our team. I believe that I can help meaningfully advance the Company’s commitment to achieving ESG goals.”
Ms. Grimaldi graduated with a BA in Psychology with high honors from Javeriana University, a top three university in Colombia, and an MBA with high honors from Meredith College in North Carolina. She has completed Executive Education courses on SEC compliance, finance from UVA, and corporate governance from the Columbia Business School. By the end of this calendar year, she plans to complete the National Association of Corporate Directors (NACD) Directorship Certification program. She is fluent in both English and Spanish. Ms. Grimaldi’s experience, education, training, and deep knowledge of the Company and its businesses, make her well qualified to serve as a director on IGC’s Board.
About IGC:
India Globalization Capital, Inc. (IGC), headquartered in Maryland, engages in the development of cannabinoid-based therapies for healthcare applications. IGC recently completed the first Phase 1 safety and tolerability clinical trial for patients suffering from Alzheimer’s disease using a THC-based investigational new drug candidate. The Company also operates an infrastructure business based in India. www.igcinc.us, www.igcpharma.com.
What is the significance of Claudia Grimaldi's appointment to the IGC Board?
Claudia Grimaldi's appointment as a non-independent Director may enhance the Board's diversity and bring valuable insights from her extensive experience with IGC.
When was Claudia Grimaldi appointed to the IGC Board?
Claudia Grimaldi was appointed to the IGC Board on March 23, 2022.
What are IGC's recent clinical trial milestones?
IGC recently completed a Phase 1 clinical trial for its THC-based investigational drug candidate targeting Alzheimer's disease.
What goals does Claudia Grimaldi aim to achieve on the IGC Board?
Claudia Grimaldi aims to help advance IGC’s commitment to achieving ESG goals and contribute to the development of therapies for neuropsychiatric symptoms in Alzheimer’s patients.
